GlobeNewsWire
13 Jun 2026, 12:20 UTC · 3h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
The U.S. Department of Justice (DOJ) is conducting an investigation into trading in Regencell Bioscience (RGC) ordinary shares, involving subpoenas for corporate operational, financial, and accounting documents. — DOJ investigations into market manipulation and accounting typically signal severe regulatory risk and can lead to massive fines or executive turnover.
-0.80A federal securities class action lawsuit has been filed against Regencell alleging that the company made false or misleading statements regarding its vulnerability to market manipulation. — Class action lawsuits create significant contingent liabilities and damage investor confidence in company management.
-0.60Regencell has warned it expects to incur significant legal costs and may face fines, penalties, or damages that exceed its insurance coverage. — Directly threatens the company's balance sheet and cash reserves via unhedged legal expenses and penalties.
-0.50Continue reading
6 related stories
Top 3 movers · tap to explore
Which stocks this story touches
The company is facing a federal securities class action lawsuit and a DOJ investigation into market manipulation and trading activity.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
